COMMENCED ACTIVITIES ON NANOPARTICLES We have long believed that some of the more dramatic outcomes that flow from the use of Mix&Go become more obvious with increasing miniaturisation. The clinical testing environment (IVD market) is trending toward the use of smaller particles and, it could therefore be argued, into our “sweet spot”. Miniaturisation allows more tests to be undertaken on smaller quantities of precious clinical samples. The smallest particles into which we have invested significant resources to date have been the 500nm beads produced by the French firm, Ademtech. We are now generating some promising early data from particles as small as 10nm (10-8 metres) – about the thickness of a bacterial cell wall. This is taking us into virgin territory and is potentially ground-breaking commercially interesting work. One of the largest players in point of care testing is taking a deep interest in the outcomes of this work.
Search Ademtech and Philips Magnotech :)
ADO Price at posting:
6.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)